Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Mhatre SP, Muranjan M, Gogtay NJ. Economic burden of Gaucher disease at a tertiary care public hospital in Mumbai. Indian J Pediatr. 2023. https://doi.org/10.1007/s12098-023-04740-4.
2. Connock M, Burls A, Frew E, et al. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher’s disease: a systematic review. Health Technol Assess. 2006;10:iii–iv, ix–136.
3. Katsigianni EI, Petrou P. A systematic review of economic evaluations of enzyme replacement therapy in lysosomal storage diseases. Cost Eff Resour Alloc. 2022;20:51.
4. van Dussen L, Biegstraaten M, Hollak CEM, Dijkgraaf MGW. Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease. Orphanet J Rare Dis. 2014;9:51.
5. National Policy for Rare Diseases 2021 | Ministry of Health and Family Welfare | GOI [Internet]. Available at: https://main.mohfw.gov.in/?q=newshighlights-45. Accessed on 18 Dec 2023.